Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival

Kaya, Vildan; Aksu, Melek Gamze; Korcum, Aylin Fidan; Özdemir, Beyza; Çeçen, Yiğit; Sindir, Bora; Genç, Mine
June 2014
International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 5, p1336
Academic Journal
Objective: Low-grade gliomas compose 5-20% of all glial tumors. The prognosis of the disease can be anticipated by specific clinical factors determined during diagnosis. For this purpose, our study investigated the clinical prognostic factors for low-grade gliomas. Methods: Patients diagnosed with histopathologically confirmed low-grade glioma, followed by Akdeniz University and Süleyman Demirel University School of Medicine, Department of Radiation Oncology between 1999 and 2013 were included in the study. The examination of survival by single variable analyses were performed by log rank test. For the multivariate analysis, independent factors for the prediction of survival by using possible factors determined by previous analyses were examined by using Cox regression analysis. Results: Fifty-five patients were included in the study. The mean follow-up period was determined as 60 ± 57 (4.5-168.1) months. Five-year overall survival was determined as 69% and 10-year overall survival was determined as 40%. When the potential prognostic factors were studied in Cox regression model, pre-radiotherapy age below 40 and gross-total excision were determined as good prognostic factors. Conclusion: We demonstrated that the aggressive surgical resection provided a better survival advantage both in single variable analyses and multivariate analyses. Consequently, although the low number of patients was the most important limitation in our study, we consider that patient age and extent of resection are the most important clinical prognostic factors in low-grade gliomas.


Related Articles

  • Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Nagane, Motoo; Kobayashi, Keiichi; Tanaka, Masaki; Tsuchiya, Kazuhiro; Shishido-Hara, Yukiko; Shimizu, Saki; Shiokawa, Yoshiaki // International Journal of Clinical Oncology;Feb2014, Vol. 19 Issue 1, p16 

    Background: Recurrent glioblastoma after initial radiotherapy plus concomitant and adjuvant temozolomide is problematic. Here, patients with temozolomide-refractory high-grade gliomas were treated with bevacizumab (BV) and evaluated using apparent diffusion coefficient (ADC) for response....

  • Going past the data for temozolomide. Villano, J.; Letarte, Nathalie; Bressler, Linda // Cancer Chemotherapy & Pharmacology;Apr2012, Vol. 69 Issue 4, p1113 

    The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the...

  • Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. Williams, Matt; Liu, Zi; Woolf, David; Hargreaves, Sarah; Michalarea, Vasiliki; Menashy, Rebecca; Kooner, Ishminder; Wilson, Elena // Journal of Cancer Research & Clinical Oncology;Oct2012, Vol. 138 Issue 10, p1683 

    Background: Radiotherapy plus concomitant and adjuvant temozolomide (RCAT) is now standard treatment for grade IV glioblastoma (GBM). We report the results from our 7 years experience of using RCAT, and the potential role of a change in platelet count as a prognostic factor. Methods: We...

  • Atypical teratoid/rhabdoid tumors: the need for more active therapeutic measures in younger patients. Lee, Ji; Kim, In-Kyeong; Phi, Ji; Wang, Kyu-Chang; Cho, Byung-Kyu; Park, Sung-Hye; Ahn, Hyo; Kim, Il; Kim, Seung-Ki // Journal of Neuro-Oncology;Apr2012, Vol. 107 Issue 2, p413 

    Despite active and aggressive therapeutic measures, atypical teratoid/rhabdoid tumors (AT/RTs) are without doubt one of the most malignant brain tumors that occur during childhood. These tumors are more prevalent in children less than 3 years of age, and the prognosis is worse in these young...

  • Health-related quality of life during adjuvant radiotherapy in breast cancer. Luutonen, Sinikka; Sintonen, Harri; Stormi, Teija; Salminen, Eeva // Quality of Life Research;May2014, Vol. 23 Issue 4, p1363 

    Objective: In this study, health- related quality of life (HRQoL) and its determinants were assessed in breast cancer patients undergoing postoperative adjuvant radiotherapy. The aim was to improve our understanding of patient's situation at the end of adjuvant treatment, as the return to every...

  • Adjuvant therapy in stage II thymic carcinoma. Song, Zhengbo; Zhang, Yiping // Journal of Cancer Research & Clinical Oncology;Feb2014, Vol. 140 Issue 2, p349 

    Purpose: The aim of this study is to investigate the impact of chemotherapy and/or radiotherapy on disease-free survival and overall survival for patients with stage II thymic carcinoma. Methods: We retrospectively evaluated the outcome of 31 patients with Masaoka stage II thymic carcinoma who...

  • A multi-center retrospective analysis of treatment effects and quality of life in adult patients with cranial ependymomas. Dützmann, Stephan; Schatlo, Bawarjan; Lobrinus, Alexander; Murek, Michael; Wostrack, Maria; Weiss, Carolin; Schaller, Karl; Raabe, Andreas; Meyer, Bernhard; Goldbrunner, Roland; Franz, Kea; Seifert, Volker; Senft, Christian // Journal of Neuro-Oncology;Oct2013, Vol. 114 Issue 3, p319 

    Long term quality of life data of adult patients harboring intracranial ependymomas have not been reported. The role of adjuvant radiation therapy in Grade II ependymomas is unclear and differs from study to study. We therefore sought to retrospectively analyze outcome and quality of life of...

  • Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications. Hav, Monirath; Libbrecht, Louis; Ferdinande, Liesbeth; Geboes, Karen; Pattyn, Piet; Cuvelier, Claude A. // BioMed Research International;10/5/2015, Vol. 2015, p1 

    Neoadjuvant radio(chemo)therapy is increasingly used in rectal cancer and induces a number of morphologic changes that affect prognostication after curative surgery, thereby creating new challenges for surgical pathologists, particularly in evaluating morphologic changes and tumour response to...

  • High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome. Viani, Gustavo A.; Patia, Barbara F.; Pellizzon, Antonio C.; De Melo, Marcel D.; Novaes, Paulo E.; Fogaroli, Ricardo C.; Conte, Maria A.; Salvajoli, Joao V. // Radiation Oncology;2006, Vol. 1, p24 

    Purpose: To report the relapse and survival rates associated to treatment for patients with stage IC, grade 2 or grade 3 and IB grade 3 diseases considered high risk patients group for relapse. Materials and methods: From January 1993 to December 2003, 106 patients with endometrial cancer stage...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics